Copyright
©The Author(s) 2021.
World J Hepatol. Feb 27, 2021; 13(2): 233-241
Published online Feb 27, 2021. doi: 10.4254/wjh.v13.i2.233
Published online Feb 27, 2021. doi: 10.4254/wjh.v13.i2.233
Figure 1 Knowledge of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis among physicians.
NAFLD: Non-alcoholic fatty liver disease; NASH: Non-alcoholic steatohepatitis.
Figure 2 Diagnosis measures for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis by physician specialty.
NASH: Non-alcoholic steatohepatitis.
Figure 3 Diagnostic techniques used in non-alcoholic steatohepatitis physicians of different specialties.
MRE: Magnetic resonance elastography; VCTE: Vibration-controlled transient elastography; CT: Computed tomography.
Figure 4 The non-alcoholic steatohepatitis patient recruitment screening pathway.
LFT: Liver function test; FBC: Full blood count; INR: International normalized ratio; PT: Prothrobmin time; PTT: Partial thromboplastin time; CAP: Controlled attenuation parameter; PCV: Porcine circovirus; NAFLD: Non-alcoholic fatty liver disease; FIB: Fibrosis.
- Citation: Wessels DH, Rosenberg Z. Awareness of non-alcoholic steatohepatitis and treatment guidelines: What are physicians telling us? World J Hepatol 2021; 13(2): 233-241
- URL: https://www.wjgnet.com/1948-5182/full/v13/i2/233.htm
- DOI: https://dx.doi.org/10.4254/wjh.v13.i2.233